Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers potent efficacy, while its selectivity provides a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch tracking series will examine how the perception and performance of Ocrevus evolves through year one in an MS market still waiting for the DMT that balances efficacy and risk better than Tysabri or Tecfidera and in a field that perennially debates the merits of early, aggressive intervention.

What you will learn in this content:

  • What is U.S. neurologists’ awareness of and familiarity with Ocrevus, and what are their perceptions of this product?
  • For which patients are neurologists prescribing Ocrevus, what are their reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What are the promotional messages and activities that Genentech and Roche are employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare with other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product description:

Launch Tracking: Ocrevus Wave 1 (US) Relapsing Forms of Multiple Sclerosis is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Ocrevus Relapsing Forms of Multiple Sclerosis - Wave 1 (US)
    • Key Findings
    • Benchmarking Ocrevus's Launch Success vs. the Competition
      • One Month Postlaunch, Ocrevus Appears to Be in a Strong Competitive Position
    • Prescriber and Nonprescriber Profiles
      • Differences Between Ocrevus Prescribers and Nonprescribers for Relapsing Forms of MS
    • Ocrevus Awareness and Perceptions
      • Unaided and Aided Awareness of Ocrevus
        • Unaided Awareness of Ocrevus Is Substantial One Month Postlaunch
      • Familiarity with Ocrevus
        • Nearly All Respondents Reported Moderate to High Familiarity with Ocrevus
      • Sources of Familiarity with Ocrevus
        • Sources of Familiarity with Ocrevus at One Month Postlaunch Have Been Academic in Nature
      • Initial Reaction to and Interest in Ocrevus
        • Surveyed Neurologists' Initial Reaction to Ocrevus is Favorable and Interest Level Is High
      • Impressions of Ocrevus
        • Surveyed Neurologists Have a Favorable Impression of Ocrevus's Risk/Benefit Profile in Relapsing Forms of MS
      • Prescriber and Nonprescriber Profiles
        • Early Prescribers of Ocrevus Have Larger Practices and Treat More Relapsing SP-MS Patients Than Nonprescribers
    • Ocrevus Trial and Use
      • Willingness to Prescribe Ocrevus
      • Number of Patients Currently Receiving Ocrevus
        • Nearly Half of Neurologists Surveyed Have Prescribed Ocrevus for Relapsing Forms of MS at One Month Postlaunch
      • Reasons for Not Yet Prescribing Ocrevus
        • Short Time on the Market, Lack of Familiarity, and Safety Are Among the Key Constraints on Ocrevus Prescribing for Relapsing Forms of MS at One Month Postlaunch
      • Anticipated Ocrevus Use
        • Surveyed Neurologists Project Strong Uptake for Ocrevus in the Relapsing MS Market in the Next Six Months
      • Ocrevus Performance on Key Attributes
        • One Month Postlaunch, Prescribers Express High Satisfaction with Ocrevus, and Many Perceive the Drug to Be Superior to Other MAbs on Safety
    • Effectiveness of Face-to-Face Detailing for Ocrevus
      • Ocrevus Sales Representative Frequency and Reach
        • Approximately One-Third of Wave 1 Respondents Have Not Been Visited by an Ocrevus Representative
      • Satisfaction with Ocrevus Sales Representative
      • Ocrevus Message Recall
        • Efficacy, Labeling, Safety, and Dosing Frequency Are Top of Mind for Neurologists After Recent Detailing of Ocrevus
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Additional Primary Market Research

Author(s): Natalie Taylor, PhD; Jonathan Searles; Sarah Soucy

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


Related Reports

Multiple Sclerosis | Access and Reimbursement | US | 2017`

The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (D...

View Details

Multiple Sclerosis | Access & Reimbursement | Detailed, Expanded Analysis (US)

The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMT

View Details

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will...

View Details

Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2018

With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the trea...

View Details